Extensively drug-resistant Pseudomonas aeruginosa: risk of bloodstream infection in hospitalized patients. 2012

C Peña, and S Gómez-Zorrilla, and C Suarez, and M A Dominguez, and F Tubau, and O Arch, and A Oliver, and M Pujol, and J Ariza
Infectious Diseases Service, IDIBELL, Hospital Universitari de Bellvitge, Barcelona, Spain. cpena@bellvitgehospital.cat

Several studies have suggested that resistance determinants usually reduce virulence. However, their contribution to decrease bloodstream infections is unclear. Our aim was to identify risk factors of extensively drug-resistant (XDR) Pseudomonas aeruginosa (PA) bacteremia and to assess the prevalence of XDR-PA bacteremia. A retrospective study of PA bloodstream infections in our patient population with at least one clinical sample isolate due to PA (2006-2007) was carried out. A total of 2,131 patients with PA clinical samples were detected. Among 1,657 patients with susceptible-PA isolates, 95 developed PA-susceptible bacteremia. Concomitantly, among 474 patients with multidrug-resistant (MDR)-PA isolates, 265 with XDR-PA, and 209 with non-XDR MDR-PA, 43 developed XDR-PA bacteremia and 13 non-XDR MDR-PA bacteremia, respectively. Pulsed-field gel electrophoresis (PFGE) revealed the clonal nature of the two predominant XDR-PA phenotypes and genetic heterogeneity in non-XDR MDR-PA phenotypes. The proportion of XDR-PA bacteremia was higher than the proportion of bacteremia in the susceptible-PA population (16 % vs. 6 %; p < 0.001). A logistic regression model identified prior exposure to fluoroquinolones [odds ratio (OR) 2.80; 95 % confidence interval (CI) 1.02 to 7.70] as the independent variable associated with XDR-PA bacteremia. Our study suggests that XDR-PA strains have a greater ability to develop bacteremia. It remains unclear as to whether this invasive capacity depends on clonal traits or on other virulence determinants.

UI MeSH Term Description Entries
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D005260 Female Females
D006760 Hospitalization The confinement of a patient in a hospital. Hospitalizations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

C Peña, and S Gómez-Zorrilla, and C Suarez, and M A Dominguez, and F Tubau, and O Arch, and A Oliver, and M Pujol, and J Ariza
January 2018, PloS one,
C Peña, and S Gómez-Zorrilla, and C Suarez, and M A Dominguez, and F Tubau, and O Arch, and A Oliver, and M Pujol, and J Ariza
January 2023, Infection and drug resistance,
C Peña, and S Gómez-Zorrilla, and C Suarez, and M A Dominguez, and F Tubau, and O Arch, and A Oliver, and M Pujol, and J Ariza
December 2012, Antimicrobial agents and chemotherapy,
C Peña, and S Gómez-Zorrilla, and C Suarez, and M A Dominguez, and F Tubau, and O Arch, and A Oliver, and M Pujol, and J Ariza
April 2015, Antimicrobial agents and chemotherapy,
C Peña, and S Gómez-Zorrilla, and C Suarez, and M A Dominguez, and F Tubau, and O Arch, and A Oliver, and M Pujol, and J Ariza
January 2018, BMJ case reports,
C Peña, and S Gómez-Zorrilla, and C Suarez, and M A Dominguez, and F Tubau, and O Arch, and A Oliver, and M Pujol, and J Ariza
March 2024, Journal of global antimicrobial resistance,
C Peña, and S Gómez-Zorrilla, and C Suarez, and M A Dominguez, and F Tubau, and O Arch, and A Oliver, and M Pujol, and J Ariza
March 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
C Peña, and S Gómez-Zorrilla, and C Suarez, and M A Dominguez, and F Tubau, and O Arch, and A Oliver, and M Pujol, and J Ariza
August 2014, Infection,
C Peña, and S Gómez-Zorrilla, and C Suarez, and M A Dominguez, and F Tubau, and O Arch, and A Oliver, and M Pujol, and J Ariza
May 2020, Antimicrobial resistance and infection control,
C Peña, and S Gómez-Zorrilla, and C Suarez, and M A Dominguez, and F Tubau, and O Arch, and A Oliver, and M Pujol, and J Ariza
January 2011, Haematologica,
Copied contents to your clipboard!